NERV - Minerva Neurosciences, Inc.

6.43
-0.145   -2.255%

Share volume: 168,524
Last Updated: 04-27-2026
Pharmaceutical Products/Pharmaceutical Preparations: -0.11%

PREVIOUS CLOSE
CHG
CHG%
$6.58
-0.15
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
6%
Profitability 0%
Dept financing 10%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.86%
1 Month
7.71%
3 Months
54.20%
6 Months
39.78%
1 Year
259.22%
2 Year
166.80%
Key data
Stock price
$6.43
P/E Ratio 
N/A
DAY RANGE
$6.39 - $6.90
EPS 
-$34.67
52 WEEK RANGE
$1.30 - $12.46
52 WEEK CHANGE
$272.75
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
43.274 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-30-2025
BETA 
-0.04
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$178,663
AVERAGE 30 VOLUME 
$207,536
Company detail
CEO: Rémy H. Luthringer
Region: US
Website: minervaneurosciences.com
Employees: 9
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Minerva Neurosciences, Inc. focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for schizophrenia; MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for Parkinson's disease and other neurodegenerative disorders.

Recent news